The bill amends various sections of the Idaho Code concerning controlled substances, specifically updating the classifications and definitions of drugs within Schedule I through Schedule V. It introduces new substances, including various fentanyl analogs such as Beta-methylacetyl fentanyl and Brorphine, into Schedule I due to their high potential for abuse and lack of accepted medical use. Additionally, the bill removes certain substances from the schedules, such as N-ethylpentylone and PeGACLONE, while also clarifying the definitions of stimulant and depressant substances. The amendments aim to enhance the regulation of controlled substances in Idaho, ensuring that the laws remain current with emerging drug trends.

Moreover, the bill revises registration requirements for individuals and entities involved with controlled substances, changing the registration frequency from annually to biennially. It establishes a controlled substances prescriptions database, detailing access protocols and penalties for unauthorized disclosure of information. The bill also outlines disciplinary actions that the board may take against registrants, ensuring due process before any penalties are imposed. With an emergency declaration, the act is set to take effect on July 1, 2026, reflecting the urgency of addressing the opioid crisis and the proliferation of synthetic drugs.

Statutes affected:
Bill Text: 37-2705, 37-2707, 37-2709, 37-2711, 37-2713, 37-2716, 37-2717, 37-2718, 37-2719, 37-2720, 37-2722, 37-2726, 37-2731